To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure firstname.lastname@example.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Uterine fibroids are the most common benign tumour in premenopausal women, with a lifetime prevalence of almost 70% in Caucasian women and more than 80% in women of Afro-Caribbean descent. About half of these women experience symptoms, with the most common being menorrhagia, dysmenorrhoea, pressure symptoms and infertility. Whilst hysterectomy is still the most commonly offered and performed operation to treat uterine fibroids, over the last 20 years minimally invasive therapies have been gaining popularity and uterine fibroid embolization is now a mainstream option for most women who wish to preserve their uterus. Since its introduction, a strong body of evidence has built demonstrating safety and efficacy with low rates of complication. Uterine fibroid embolization (UFE) was first described as a treatment for symptomatic leiomyomas in 1995 by Ravina et al. and has proved so popular that in the last year there were over 25,000 uterine fibroid embolization procedures performed worldwide .
Email your librarian or administrator to recommend adding this to your organisation's collection.